Stocktoria
Oncology Institute, Inc. TOI
Oncology Institute, Inc. (TOI) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $502.7M at a -12.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.254 |
| Retained earnings / assets | -1.648 |
| EBIT / assets | -0.219 |
| Equity / liabilities | -0.087 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TOI | Oncology Institute, Inc. | 4/9 | -5.27 | — | +27.8% |
| LFMD | LifeMD, Inc. | 5/9 | -9.85 | 13.9 | +25.3% |
| SBC | SBC Medical Group Holdings Inc | 3/9 | 8.55 | 6.7 | -15.5% |
| AIRS | Airsculpt Technologies, Inc. | 3/9 | -0.63 | — | -15.8% |
| CCM | Concord Medical Services Holdings Ltd | 6/9 | -3.98 | — | +25.2% |
| HIMS | Hims & Hers Health, Inc. | 4/9 | 1.61 | 61.2 | +59% |
| TDOC | Teladoc Health, Inc. | 5/9 | -16.73 | — | -1.5% |
About Oncology Institute, Inc.
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
FAQ
Is TOI financially healthy?
Oncology Institute, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does TOI pay a dividend?
No, Oncology Institute, Inc. does not currently pay a dividend.
How profitable is TOI?
In FY2025, Oncology Institute, Inc. had a net margin of -12.1%.
What is the analyst price target for TOI?
The average Wall-Street price target for Oncology Institute, Inc. is $7.75, from 4 analysts (consensus: strong buy).
Is TOI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Oncology Institute, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.